{"id":59278,"date":"2026-03-11T16:21:35","date_gmt":"2026-03-11T08:21:35","guid":{"rendered":"https:\/\/flcube.com\/?p=59278"},"modified":"2026-03-11T16:21:36","modified_gmt":"2026-03-11T08:21:36","slug":"zelgens-zesuning-launches-nationwide-first-china-approved-recombinant-tsh-for-thyroid-cancer-follow-up","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59278","title":{"rendered":"Zelgen&#8217;s Zesuning Launches Nationwide \u2013 First China-Approved Recombinant TSH for Thyroid Cancer Follow-Up"},"content":{"rendered":"\n<p><strong>Suzhou Zelgen Biopharmaceuticals Co., Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688266:SHA\">SHA: 688266<\/a>) announced the <strong>nationwide commercial launch<\/strong> of <strong>Zesuning (injectable human thyrotropin \u03b2)<\/strong>, the <strong>first approved recombinant human thyrotropin injection in China<\/strong> for <strong>differentiated thyroid cancer (DTC) follow-up after total\/near-total thyroidectomy<\/strong>. The <strong>first batch shipment completion<\/strong> marks the <strong>in-market debut<\/strong> of Zelgen&#8217;s <strong>proprietary IP asset<\/strong>, which eliminates the need for <strong>thyroid hormone withdrawal<\/strong> during postoperative assessment, improving <strong>patient compliance and quality of life<\/strong> while maintaining <strong>93.6% diagnostic concordance<\/strong> with traditional methods.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-commercial-launch-milestone\">Commercial Launch Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>Zesuning (recombinant human thyrotropin \u03b2 injection)<\/td><\/tr><tr><td><strong>Developer<\/strong><\/td><td>Suzhou Zelgen Biopharmaceuticals (SHA: 688266) \u2013 independently developed; proprietary IP<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Recombinant human thyrotropin (rhTSH)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Collaborative diagnosis during DTC follow-up: serum thyroglobulin (Tg) detection \u00b1 radioactive iodine (\u00b9\u00b3\u00b9I) whole-body scan (WBS)<\/td><\/tr><tr><td><strong>Innovation<\/strong><\/td><td>First China-approved rhTSH; eliminates thyroid hormone withdrawal requirement<\/td><\/tr><tr><td><strong>Launch Scope<\/strong><\/td><td>Nationwide China<\/td><\/tr><tr><td><strong>First Shipment<\/strong><\/td><td>Completed (March 2026)<\/td><\/tr><tr><td><strong>Commercial Partner<\/strong><\/td><td>Merck (exclusive China rights \u2013 June 2025 agreement)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-amp-differentiation\">Clinical Evidence &amp; Differentiation<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Zesuning Performance<\/th><th>Traditional Thyroid Hormone Withdrawal<\/th><th>Clinical Advantage<\/th><\/tr><\/thead><tbody><tr><td><strong>WBS Concordance<\/strong><\/td><td>88.2%<\/td><td>Reference standard<\/td><td>Comparable diagnostic accuracy<\/td><\/tr><tr><td><strong>Tg Detection Concordance<\/strong><\/td><td>90.4%<\/td><td>Reference standard<\/td><td>Reliable thyroglobulin measurement<\/td><\/tr><tr><td><strong>Combined Concordance<\/strong><\/td><td><strong>93.6%<\/strong><\/td><td>\u2014<\/td><td>High overall diagnostic fidelity<\/td><\/tr><tr><td><strong>Hypothyroidism Symptoms<\/strong><\/td><td><strong>Eliminated<\/strong><\/td><td>Severe (fatigue, depression, cognitive impairment)<\/td><td><strong>Major quality-of-life improvement<\/strong><\/td><\/tr><tr><td><strong>Patient Compliance<\/strong><\/td><td><strong>Enhanced<\/strong><\/td><td>Poor (withdrawal period 3-4 weeks)<\/td><td><strong>Improved follow-up adherence<\/strong><\/td><\/tr><tr><td><strong>Emotional Well-being<\/strong><\/td><td><strong>Improved<\/strong><\/td><td>Significant distress during withdrawal<\/td><td><strong>Psychological benefit<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Mechanism:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Rapid TSH Elevation:<\/strong> Exogenous rhTSH stimulates residual thyroid tissue\/lesions without stopping levothyroxine<\/li>\n\n\n\n<li><strong>Iodine Uptake:<\/strong> Enables \u00b9\u00b3\u00b9I WBS without hormone discontinuation<\/li>\n\n\n\n<li><strong>Tg Secretion:<\/strong> Precise stimulation for accurate serum thyroglobulin measurement<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-partnership-amp-commercial-structure\">Strategic Partnership &amp; Commercial Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agreement Date<\/strong><\/td><td>June 2025<\/td><\/tr><tr><td><strong>Structure<\/strong><\/td><td>Strategic collaboration<\/td><\/tr><tr><td><strong>Zelgen Retains<\/strong><\/td><td>Manufacturing, IP ownership, ex-China rights<\/td><\/tr><tr><td><strong>Merck Role<\/strong><\/td><td>Exclusive commercialization rights in mainland China<\/td><\/tr><tr><td><strong>Strategic Rationale<\/strong><\/td><td>Zelgen leverages Merck&#8217;s established endocrinology sales infrastructure; Merck gains innovative oncology diagnostic asset<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-competitive-landscape\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>China DTC Burden<\/strong><\/td><td>~200,000 annual thyroid cancer diagnoses; 90%+ are DTC; rising incidence with improved detection<\/td><\/tr><tr><td><strong>Follow-Up Standard<\/strong><\/td><td>Thyroid hormone withdrawal (3-4 weeks) causes severe hypothyroidism; patient non-compliance common<\/td><\/tr><tr><td><strong>Global Precedent<\/strong><\/td><td>Thyrogen (rhTSH, Genzyme\/Sanofi) approved U.S.\/EU since 1990s; Zesuning first China domestic equivalent<\/td><\/tr><tr><td><strong>Pricing Power<\/strong><\/td><td>Premium positioning vs. withdrawal method; NRDL inclusion critical for access<\/td><\/tr><tr><td><strong>Diagnostic-therapeutic Integration<\/strong><\/td><td>Enables accurate \u00b9\u00b3\u00b9I therapy planning without treatment delays<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-dynamics\">Competitive Dynamics<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product<\/th><th>Developer<\/th><th>Status<\/th><th>Zesuning Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>Thyrogen (rhTSH)<\/strong><\/td><td>Genzyme\/Sanofi<\/td><td>Approved (U.S., EU, limited China access)<\/td><td>First China-developed rhTSH; domestic manufacturing cost advantage<\/td><\/tr><tr><td><strong>Thyroid Hormone Withdrawal<\/strong><\/td><td>\u2014<\/td><td>Standard of care (free)<\/td><td>Eliminates hypothyroidism burden; superior patient experience<\/td><\/tr><tr><td><strong>Zesuning<\/strong><\/td><td><strong>Zelgen<\/strong><\/td><td><strong>Launched (March 2026)<\/strong><\/td><td><strong>China proprietary IP; Merck commercialization; 93.6% concordance<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-forward-looking-priorities\">Forward-Looking Priorities<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>2026 Launch Execution:<\/strong> Hospital endocrinology\/oncology department penetration; nuclear medicine center partnerships<\/li>\n\n\n\n<li><strong>NRDL Negotiation:<\/strong> 2026-2027 national reimbursement list inclusion for volume scaling<\/li>\n\n\n\n<li><strong>Merck Integration:<\/strong> Sales force training; co-promotion with Merck&#8217;s diabetes\/endocrinology portfolio<\/li>\n\n\n\n<li><strong>Global Expansion:<\/strong> U.S.\/EU IND preparation; potential for 505(b)(2) pathway leveraging China data<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding commercial launch performance, reimbursement negotiations, and global expansion for Zesuning. Actual results may differ due to competitive dynamics with Thyrogen, pricing regulations, and diagnostic practice pattern adoption.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced the nationwide commercial launch of Zesuning (injectable&#8230;<\/p>\n","protected":false},"author":1,"featured_media":59279,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[40,905,246],"class_list":["post-59278","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-market-launch","tag-sha-688266","tag-zelgen-biopharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Zelgen&#039;s Zesuning Launches Nationwide \u2013 First China-Approved Recombinant TSH for Thyroid Cancer Follow-Up - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced the nationwide commercial launch of Zesuning (injectable human thyrotropin \u03b2), the first approved recombinant human thyrotropin injection in China for differentiated thyroid cancer (DTC) follow-up after total\/near-total thyroidectomy. The first batch shipment completion marks the in-market debut of Zelgen&#039;s proprietary IP asset, which eliminates the need for thyroid hormone withdrawal during postoperative assessment, improving patient compliance and quality of life while maintaining 93.6% diagnostic concordance with traditional methods.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=59278\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zelgen&#039;s Zesuning Launches Nationwide \u2013 First China-Approved Recombinant TSH for Thyroid Cancer Follow-Up\" \/>\n<meta property=\"og:description\" content=\"Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced the nationwide commercial launch of Zesuning (injectable human thyrotropin \u03b2), the first approved recombinant human thyrotropin injection in China for differentiated thyroid cancer (DTC) follow-up after total\/near-total thyroidectomy. The first batch shipment completion marks the in-market debut of Zelgen&#039;s proprietary IP asset, which eliminates the need for thyroid hormone withdrawal during postoperative assessment, improving patient compliance and quality of life while maintaining 93.6% diagnostic concordance with traditional methods.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=59278\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-11T08:21:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-11T08:21:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1105.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59278#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59278\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Zelgen&#8217;s Zesuning Launches Nationwide \u2013 First China-Approved Recombinant TSH for Thyroid Cancer Follow-Up\",\"datePublished\":\"2026-03-11T08:21:35+00:00\",\"dateModified\":\"2026-03-11T08:21:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59278\"},\"wordCount\":506,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59278#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1105.webp\",\"keywords\":[\"Market launch\",\"SHA: 688266\",\"Zelgen Biopharmaceuticals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59278#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59278\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=59278\",\"name\":\"Zelgen's Zesuning Launches Nationwide \u2013 First China-Approved Recombinant TSH for Thyroid Cancer Follow-Up - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59278#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59278#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1105.webp\",\"datePublished\":\"2026-03-11T08:21:35+00:00\",\"dateModified\":\"2026-03-11T08:21:36+00:00\",\"description\":\"Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced the nationwide commercial launch of Zesuning (injectable human thyrotropin \u03b2), the first approved recombinant human thyrotropin injection in China for differentiated thyroid cancer (DTC) follow-up after total\\\/near-total thyroidectomy. The first batch shipment completion marks the in-market debut of Zelgen's proprietary IP asset, which eliminates the need for thyroid hormone withdrawal during postoperative assessment, improving patient compliance and quality of life while maintaining 93.6% diagnostic concordance with traditional methods.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59278#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59278\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59278#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1105.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1105.webp\",\"width\":1080,\"height\":608,\"caption\":\"Zelgen's Zesuning Launches Nationwide \u2013 First China-Approved Recombinant TSH for Thyroid Cancer Follow-Up\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59278#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zelgen&#8217;s Zesuning Launches Nationwide \u2013 First China-Approved Recombinant TSH for Thyroid Cancer Follow-Up\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Zelgen's Zesuning Launches Nationwide \u2013 First China-Approved Recombinant TSH for Thyroid Cancer Follow-Up - Insight, China&#039;s Pharmaceutical Industry","description":"Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced the nationwide commercial launch of Zesuning (injectable human thyrotropin \u03b2), the first approved recombinant human thyrotropin injection in China for differentiated thyroid cancer (DTC) follow-up after total\/near-total thyroidectomy. The first batch shipment completion marks the in-market debut of Zelgen's proprietary IP asset, which eliminates the need for thyroid hormone withdrawal during postoperative assessment, improving patient compliance and quality of life while maintaining 93.6% diagnostic concordance with traditional methods.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=59278","og_locale":"en_US","og_type":"article","og_title":"Zelgen's Zesuning Launches Nationwide \u2013 First China-Approved Recombinant TSH for Thyroid Cancer Follow-Up","og_description":"Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced the nationwide commercial launch of Zesuning (injectable human thyrotropin \u03b2), the first approved recombinant human thyrotropin injection in China for differentiated thyroid cancer (DTC) follow-up after total\/near-total thyroidectomy. The first batch shipment completion marks the in-market debut of Zelgen's proprietary IP asset, which eliminates the need for thyroid hormone withdrawal during postoperative assessment, improving patient compliance and quality of life while maintaining 93.6% diagnostic concordance with traditional methods.","og_url":"https:\/\/flcube.com\/?p=59278","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-11T08:21:35+00:00","article_modified_time":"2026-03-11T08:21:36+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1105.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=59278#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=59278"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Zelgen&#8217;s Zesuning Launches Nationwide \u2013 First China-Approved Recombinant TSH for Thyroid Cancer Follow-Up","datePublished":"2026-03-11T08:21:35+00:00","dateModified":"2026-03-11T08:21:36+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=59278"},"wordCount":506,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=59278#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1105.webp","keywords":["Market launch","SHA: 688266","Zelgen Biopharmaceuticals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=59278#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=59278","url":"https:\/\/flcube.com\/?p=59278","name":"Zelgen's Zesuning Launches Nationwide \u2013 First China-Approved Recombinant TSH for Thyroid Cancer Follow-Up - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=59278#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=59278#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1105.webp","datePublished":"2026-03-11T08:21:35+00:00","dateModified":"2026-03-11T08:21:36+00:00","description":"Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced the nationwide commercial launch of Zesuning (injectable human thyrotropin \u03b2), the first approved recombinant human thyrotropin injection in China for differentiated thyroid cancer (DTC) follow-up after total\/near-total thyroidectomy. The first batch shipment completion marks the in-market debut of Zelgen's proprietary IP asset, which eliminates the need for thyroid hormone withdrawal during postoperative assessment, improving patient compliance and quality of life while maintaining 93.6% diagnostic concordance with traditional methods.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=59278#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=59278"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=59278#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1105.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1105.webp","width":1080,"height":608,"caption":"Zelgen's Zesuning Launches Nationwide \u2013 First China-Approved Recombinant TSH for Thyroid Cancer Follow-Up"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=59278#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Zelgen&#8217;s Zesuning Launches Nationwide \u2013 First China-Approved Recombinant TSH for Thyroid Cancer Follow-Up"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1105.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59278","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59278"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59278\/revisions"}],"predecessor-version":[{"id":59280,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59278\/revisions\/59280"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/59279"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59278"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59278"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59278"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}